Expert discusses FDA pooled analyses in lung cancer

June 21, 2022

1 min watch

Source/Disclosures

Source:

Healio Interviews

Akinboro O, et al. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50 %: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.

Nakajima EC, et al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.

Disclosures: Marmarelis reports holding stock and other ownership interests in Bluebird Bio, Gilead Sciences; Johnson & Johnson, Merck, Pfizer, and Portola Pharmaceuticals; receiving honoraria from AstraZeneca, Blueprint Medicines, Health Advances, Janssen Oncology, Novocure, Takeda, and Targeted Oncology; serving in a consulting or advisory role for AstraZeneca Boehringer Ingelheim, Bristol-Myers Squibb/Celgene, and Ikena Oncology; receiving research funding to Marmarelis’s institution from AstraZeneca, Lilly, and Trizell; receiving travel, accommodations and expenses from Boehringer Ingelheim and Novocure; and having another relationship with Novartis.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Melina MarmarelisMD, discussed results from two FDA pooled analyses in lung cancer that were presented at the ASCO annual meeting.

“We need better indicators for what is high-risk disease in order to choose patients who could benefit from chemotherapy because clearly there’s a population that can really benefit from chemotherapy, even in the high PD-L1 group,” Marmarelis, assistant professor of medicine at the University of Pennsylvania, said.

Leave a Reply

Your email address will not be published.